Polaryx Therapeutics
Healthcare & Pharmaceuticals Awards 2026
Best Pediatric Lysosomal Storage Disease Therapeutics 2026 - USA
Rare Neurodegenerative Disease Drug Development Excellence Award 2026 - USA
Rare Neurodegenerative Disease Drug Development Excellence Award 2026 - USA
Polaryx Therapeutics is advancing innovative treatments for rare pediatric neurodegenerative diseases, focusing on lysosomal storage disorders. Its scalable platform combines small-molecule and gene therapies to target both genetic causes and disease progression. Lead candidate PLX-200, an oral therapy, aims to reduce treatment burden while improving outcomes, with a Phase 2 trial set to evaluate impact across multiple conditions.